Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)

Inclusion Criteria:

* Deemed resectable or borderline resectable at baseline, confirmed by MDT evaluation at diagnosis.
* Previously untreated and pathologically confirmed Stage IIB to select \[i.e.N2\] Stage IIIB by AJCC v8.
* Nodal status confirmed with whole body FDG-PET and biopsy via endobronchial ultrasound, mediastinoscopy, or thoracoscopy.
* Mandatory brain MRI.
* EGFR and ALK wild-type.
* Medically operable: adequate cardiac and lung function to undergo resection.
* Participant must be ≥ 18 years, at the time of screening.
* Histologically or cytologically documented NSCLC.
* Minimum life expectancy of 12 weeks.
* Minimum body weight of 30 kg.
* Male and female participants must be willing to use acceptable methods of contraception.
* Female participants of childbearing potential must have negative pregnancy test.

Exclusion Criteria:

* Unresectable NSCLC confirmed by MDT evaluation at baseline
* Stage IIIC patients
* Participants whose planned surgery at enrollment is a wedge resection
* Known EGFR mutation or ALK translocation
* Participants contraindicated for surgical intervention due to comorbid conditions
* Participants who are allergic to study intervention.
* Participants with more than one primary tumour.
* Known active hepatitis infection, positive HCV antibody, HBsAg or HBV core antibody (anti-HBc), at screening.
* Female participants who are pregnant or breastfeeding.
* Judgement by the investigator that the participant should not participate in the study.
* Previously infected or tested positive for human immunodeficiency virus.